• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fibrinolytic therapy for COVID-19: a review of case series.

作者信息

Ji Hong-Long, Dai Yuling, Zhao Runzhen

机构信息

Department of Cellular and Molecular Biology, University of Texas at Tyler Health Science Center, Tyler, TX, USA.

Texas Lung Injury Institute, University of Texas at Tyler Health Science Center, Tyler, TX, USA.

出版信息

Acta Pharmacol Sin. 2022 Aug;43(8):2168-2170. doi: 10.1038/s41401-021-00827-w. Epub 2021 Dec 10.

DOI:10.1038/s41401-021-00827-w
PMID:34893684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8661828/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0823/9343351/47a7ef33ce37/41401_2021_827_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0823/9343351/47a7ef33ce37/41401_2021_827_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0823/9343351/47a7ef33ce37/41401_2021_827_Fig1_HTML.jpg

相似文献

1
Fibrinolytic therapy for COVID-19: a review of case series.COVID-19的纤维蛋白溶解疗法：病例系列综述
Acta Pharmacol Sin. 2022 Aug;43(8):2168-2170. doi: 10.1038/s41401-021-00827-w. Epub 2021 Dec 10.
2
Can fibrinolytic therapy be clinically useful in severe pneumonia caused by COVID-19?纤溶疗法在新型冠状病毒肺炎所致重症肺炎中是否具有临床应用价值？
J Thromb Thrombolysis. 2021 Apr;51(3):633-636. doi: 10.1007/s11239-020-02247-9. Epub 2020 Aug 12.
3
[Fibrinolytic therapy].
Hamostaseologie. 2008 Dec;28(5):428-37.
4
[Analysis on the efficacy and safety of fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction during the COVID-19 epidemic].[新型冠状病毒肺炎疫情期间急性ST段抬高型心肌梗死患者溶栓治疗的疗效及安全性分析]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jun 24;48(6):472-476. doi: 10.3760/cma.j.cn112148-20200331-00268.
5
Trends and Outcomes of Fibrinolytic Therapy for STEMI: Insights and Reflections in the COVID-19 Era.ST段抬高型心肌梗死的纤维蛋白溶解疗法的趋势与结果：COVID-19时代的见解与思考
JACC Cardiovasc Interv. 2020 Oct 12;13(19):2312-2314. doi: 10.1016/j.jcin.2020.07.004.
6
[Therapy of acute myocardial infarct with thrombolytic drugs. Can use of thrombolytic therapy be further improved?].
Fortschr Med. 1993 May 10;111(13):209-10, 213.
7
[Thrombolytic treatment of acute myocardial infarct. 1].
Acta Med Port. 1998 May;11(5):409-19.
8
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke.严重急性呼吸综合征冠状病毒2感染与缺血性中风
Stroke. 2020 Jul;51(7):e124-e127. doi: 10.1161/STROKEAHA.120.030153. Epub 2020 May 12.
9
[Thrombolytic therapy of pulmonary embolism].[肺栓塞的溶栓治疗]
Internist (Berl). 1992 Apr;33(4):216-24.
10
[Pharmacological basis of thrombolytic therapy].
Klin Med (Mosk). 1990 Jun;68(6):13-9.

引用本文的文献

1
Microvascular Thrombosis as a Critical Factor in Severe COVID-19.微血管血栓形成是重症 COVID-19 的关键因素。
Int J Mol Sci. 2023 Jan 27;24(3):2492. doi: 10.3390/ijms24032492.
2
Pathophysiological mechanisms of thrombosis in acute and long COVID-19.急性 COVID-19 和长新冠中的血栓形成的病理生理学机制。
Front Immunol. 2022 Nov 16;13:992384. doi: 10.3389/fimmu.2022.992384. eCollection 2022.

本文引用的文献

1
Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.组织型纤溶酶原激活剂用于重症 COVID-19 成年患者
Ann Am Thorac Soc. 2021 Nov;18(11):1917-1921. doi: 10.1513/AnnalsATS.202102-127RL.